Lopez M, Wdzieczak-Bakala J, Pradelles P, Frindel E
Inserm U.250, Institut Gustave-Roussy, Villejuif, France.
Leukemia. 1991 Mar;5(3):270-2.
In 1977, Frindel et al. reported the presence in fetal calf bone marrow of a low molecular factor, the tetrapeptide Ac-N-Ser-Asp-Lys-Pro (AcSDKP), capable of inhibiting in vivo the hematopoietic pluripotent stem cell (CFU-S) recruitment into DNA synthesis and to increase the survival of mice which had received lethal doses of cytosine arabinoside (AraC), a phase-specific drug. Considering the potential clinical importance of CFU-S proliferation inhibitor during anticancer chemotherapy and the importance of monitoring the inhibitor by immunological methods, we tried to determine if a similar inhibitor is present in humans. Preliminary results indicate the presence in human placenta of an inhibitor coeluted with AcSDKP and which is effective in inhibiting murine CFU-S.
1977年，弗里德尔等人报告在胎牛骨髓中存在一种低分子因子，即四肽Ac-N-丝氨酸-天冬氨酸-赖氨酸-脯氨酸（AcSDKP），它能够在体内抑制造血多能干细胞（CFU-S）进入DNA合成，并提高接受致死剂量阿糖胞苷（AraC，一种细胞周期特异性药物）的小鼠的存活率。考虑到CFU-S增殖抑制剂在抗癌化疗中的潜在临床重要性以及通过免疫学方法监测该抑制剂的重要性，我们试图确定人类体内是否存在类似的抑制剂。初步结果表明，人类胎盘中存在一种与AcSDKP共洗脱且能有效抑制小鼠CFU-S的抑制剂。
